Prystupa Andrzej, Kiciński Paweł, Luchowska-Kocot Dorota, Sak Jarosław, Prystupa Tomasz Karol, Tan Yung-Hsu, Panasiuk Lech, Załuska Wojciech
Department of Internal Medicine, Medical University, Lublin, Poland.
Department of Experimental Haematooncology, Medical University, Lublin, Poland.
Ann Agric Environ Med. 2019 Mar 22;26(1):143-147. doi: 10.26444/aaem/100536. Epub 2019 Jan 3.
In Poland, an increasing number of patients are hospitalized due to liver diseases. One of the common liver diseases is cirrhosis, which can be caused by alcohol, viral hepatitis, autoimmune processes and metabolic diseases.
The study included 99 patients with alcoholic cirrhosis from the Lublin region of Eastern Poland. The control group consisted of 20 healthy individuals without liver disease who did not abuse alcohol. The concentrations of serum kallistatin and chemerin were determined using ELISA kits.
The aim of the study is to evaluate serum levels of kallistatin and chemerin in patients with different stages of alcoholic liver cirrhosis.
The highest chemerin level was found in the control group - 182.6±80.4 ng/ml. In other stages of liver cirrhosis, the following levels were observed: 175.7±62.7 ng/ml in Child-Pugh stage A (Ch-P A), 150.2±59.7 ng/ml in Ch-P B and 110.3±73.6 ng/ml in Ch-P C. Significant differences in chemerin levels between controls and Ch-P C patients (p=0.01), as well as between the Ch-P A patients and Ch-P C patients (p=0.02), were demonstrated. The highest kallistatin level was demonstrated in the control group - 8.2±3.5 μg/ml. In other stages of liver cirrhosis, the following concentrations were found: 7.2±27 μg/ml in Ch-P A, 4.4±2.2 μg/ml in Ch-P B and 3.5±1.9 μg/ml in Ch-P C. Statistically significant differences were observed between controls and Ch-P B patients (p<0.001), controls and Ch-P C patients (p<0.001), Ch-P A and Ch-P B patients (p=0.01), as well as Ch-P A and Ch-P C patients (<0.001).
The levels of chemerin and kallistatin decrease with progression of liver damage during alcoholic liver cirrhosis. The impairment of its synthetic function leads to reductions in levels of the adipokines studied.
在波兰，因肝脏疾病住院的患者数量日益增加。常见的肝脏疾病之一是肝硬化，其可由酒精、病毒性肝炎、自身免疫过程和代谢疾病引起。
该研究纳入了来自波兰东部卢布林地区的99例酒精性肝硬化患者。对照组由20名无肝脏疾病且不酗酒的健康个体组成。使用酶联免疫吸附测定试剂盒测定血清卡利他汀和chemerin的浓度。
本研究旨在评估不同阶段酒精性肝硬化患者血清中卡利他汀和chemerin的水平。
对照组chemerin水平最高，为182.6±80.4 ng/ml。在肝硬化的其他阶段，观察到以下水平：Child-Pugh A期（Ch-P A）为175.7±62.7 ng/ml，Ch-P B期为150.2±59.7 ng/ml，Ch-P C期为110.3±73.6 ng/ml。对照组与Ch-P C期患者之间（p=0.01）以及Ch-P A期患者与Ch-P C期患者之间（p=0.02）的chemerin水平存在显著差异。对照组卡利他汀水平最高，为8.2±3.5 μg/ml。在肝硬化的其他阶段，发现以下浓度：Ch-P A期为7.2±2.7 μg/ml，Ch-P B期为4.4±2.2 μg/ml，Ch-P C期为3.5±1.9 μg/ml。在对照组与Ch-P B期患者之间（p<0.001）、对照组与Ch-P C期患者之间（p<0.001）、Ch-P A期与Ch-P B期患者之间（p=0.01）以及Ch-P A期与Ch-P C期患者之间（<0.001）观察到统计学上的显著差异。
在酒精性肝硬化期间，随着肝损伤的进展，chemerin和卡利他汀水平降低。肝脏合成功能受损导致所研究的脂肪因子水平降低。
